ASHPOfficial

In this episode, Renee Robinson, Cathy Oliphant and Mary Spatafore discuss the INTERACT program, whose goals are to better prepare rural healthcare providers to provide safe and effective COVID-19 outpatient treatment, improving healthcare service utilization and health outcomes of patients diagnosed with COVID-19. This includes assessing and meeting unmet drug-drug training and support needs for pharmacists treating patients for COVID-19 in the outpatient setting. 

The information presented during the podcast reflects solely the opinions of the presenter. The information and materials are not, and are not intended as, a comprehensive source of drug information on this topic. The contents of the podcast have not been reviewed by ASHP, and should neither be interpreted as the official policies of ASHP, nor an endorsement of any product(s), nor should they be considered as a substitute for the professional judgment of the pharmacist or physician.

This podcast will provide members an overview of where FDA draft guidance for hospital and health system compounding stands. We’ll provide a refresher on the guidance, as well as a discussion on how the revised USP chapters might impact practice compliance and what comes next with FDA advocacy. 

The information presented during the podcast reflects solely the opinions of the presenter. The information and materials are not, and are not intended as, a comprehensive source of drug information on this topic. The contents of the podcast have not been reviewed by ASHP, and should neither be interpreted as the official policies of ASHP, nor an endorsement of any product(s), nor should they be considered as a substitute for the professional judgment of the pharmacist or physician.

In this podcast, we will be discussing how telehealth has been utilized to deliver pharmacy services within the ambulatory care setting and its impact on outcomes. This podcast also explores ASHP’s strategic initiatives and efforts in the areas of telehealth, digital health, and data driven healthcare as pharmacists and other providers begin to think innovatively about how care is delivered now and in the future. 

The information presented during the podcast reflects solely the opinions of the presenter. The information and materials are not, and are not intended as, a comprehensive source of drug information on this topic. The contents of the podcast have not been reviewed by ASHP, and should neither be interpreted as the official policies of ASHP, nor an endorsement of any product(s), nor should they be considered as a substitute for the professional judgment of the pharmacist or physician.

Many practitioners find as they grow in their practice that they move into leadership roles.  These roles can come after completing a PGY2 in Emergency Medicine or during their career. This podcast will the transition two pharmacists have done as they moved from practicing as emergency medicine pharmacists into taking leadership roles over emergency medicine pharmacy practices. 

The information presented during the podcast reflects solely the opinions of the presenter. The information and materials are not, and are not intended as, a comprehensive source of drug information on this topic. The contents of the podcast have not been reviewed by ASHP, and should neither be interpreted as the official policies of ASHP, nor an endorsement of any product(s), nor should they be considered as a substitute for the professional judgment of the pharmacist or physician.

ASHP conducted two surveys in late 2021 better understand how ASHP can promote technician development through the advancement of patient care roles and increased responsibilities, and address recruitment and retention issues within the technician workforce. Executive Committee Members of the Pharmacy Technician Forum and Section of Pharmacy Practice Leaders meet during the 2022 ASHP Summer Meetings in Phoenix, AZ to reflect on the key findings identified from these surveys. 

The information presented during the podcast reflects solely the opinions of the presenter. The information and materials are not, and are not intended as, a comprehensive source of drug information on this topic. The contents of the podcast have not been reviewed by ASHP, and should neither be interpreted as the official policies of ASHP, nor an endorsement of any product(s), nor should they be considered as a substitute for the professional judgment of the pharmacist or physician.

Acute pain management can be challenging, especially in patients receiving chronic opioid therapy. Multimodal therapy using a combination of pharmacologic and non-pharmacologic interventions provides a synergistic approach to treating moderate to severe pain versus use of opioid monotherapy for pain control.  This session will review multimodal interventions recommended for acute pain management and highlight approaches for acute pain control in the opioid tolerant patient. 

The information presented during the podcast reflects solely the opinions of the presenter. The information and materials are not, and are not intended as, a comprehensive source of drug information on this topic. The contents of the podcast have not been reviewed by ASHP, and should neither be interpreted as the official policies of ASHP, nor an endorsement of any product(s), nor should they be considered as a substitute for the professional judgment of the pharmacist or physician.

This podcast is a follow-up to the October webinar, A Day in the Life: Improving Collaboration to Minimize Exposure to Hazardous Drugs from Preparation to Administration and Beyond. Our experts will address audience questions that they were unable to answer during the webinar.

The information presented during the podcast reflects solely the opinions of the presenter. The information and materials are not, and are not intended as, a comprehensive source of drug information on this topic. The contents of the podcast have not been reviewed by ASHP, and should neither be interpreted as the official policies of ASHP, nor an endorsement of any product(s), nor should they be considered as a substitute for the professional judgment of the pharmacist or physician.

This podcast will focus on therapies for HIV management. The primary focus will be on new and emerging pipeline therapies in addition to what pharmacists can do to promote access and adherence.

The information presented during the podcast reflects solely the opinions of the presenter. The information and materials are not, and are not intended as, a comprehensive source of drug information on this topic. The contents of the podcast have not been reviewed by ASHP, and should neither be interpreted as the official policies of ASHP, nor an endorsement of any product(s), nor should they be considered as a substitute for the professional judgment of the pharmacist or physician.

Health system mergers and acquisitions provide unique opportunities for pharmacy leadership as well as unique challenges. This podcast is going to address how different pharmacy leaders have approached governance and assigning responsibilities during these transitions. 

The information presented during the podcast reflects solely the opinions of the presenter. The information and materials are not, and are not intended as, a comprehensive source of drug information on this topic. The contents of the podcast have not been reviewed by ASHP, and should neither be interpreted as the official policies of ASHP, nor an endorsement of any product(s), nor should they be considered as a substitute for the professional judgment of the pharmacist or physician.

In this podcast, Dr. Francesca Cunningham, Dr. Joseph DiPiro, and Dr. Scott Nelson discuss the 2023 ASHP/ASHP Foundation Pharmacy Forecast Report with host and AJHP Editor in Chief Dr. Daniel Cobaugh.

The information presented during the podcast reflects solely the opinions of the presenter. The information and materials are not, and are not intended as, a comprehensive source of drug information on this topic. The contents of the podcast have not been reviewed by ASHP, and should neither be interpreted as the official policies of ASHP, nor an endorsement of any product(s), nor should they be considered as a substitute for the professional judgment of the pharmacist or physician.